LDL, Non-HDL Cholesterol, and Apolipoprotein B and Risk of Cardiovascular Events in Statin-Treated Patients: A Meta-Analysis

Once a patient is on a statin, which number best tracks their remaining risk — LDL cholesterol, non-HDL cholesterol, or apolipoprotein B? This meta-analysis of more than 62,000 statin-treated patients tackled that practical question.

The answer favored looking beyond LDL. All three measures predicted events, but non-HDL cholesterol was most strongly associated with cardiovascular risk on treatment, significantly outperforming LDL cholesterol. ApoB also edged out LDL, though in this particular analysis its advantage over LDL did not reach statistical significance. The practical recommendation that followed was that non-HDL cholesterol — a free calculation requiring no extra test — is a better target for monitoring treated patients than LDL alone.

The finding matters because LDL is most misleading exactly where it counts: at low, treated levels and in patients with metabolic disturbance. Non-HDL and apoB capture the residual atherogenic particles the LDL number can underestimate.

We rate the evidence strong. It is a large, well-constructed meta-analysis that helped move guidelines toward non-HDL cholesterol as a secondary treatment target, reinforcing the broader shift away from LDL as the sole yardstick.